vs

Side-by-side financial comparison of CLOVER HEALTH INVESTMENTS, CORP. (CLOV) and ITRON, INC. (ITRI). Click either name above to swap in a different company.

ITRON, INC. is the larger business by last-quarter revenue ($587.0M vs $487.7M, roughly 1.2× CLOVER HEALTH INVESTMENTS, CORP.). ITRON, INC. runs the higher net margin — 9.1% vs -10.1%, a 19.2% gap on every dollar of revenue. On growth, CLOVER HEALTH INVESTMENTS, CORP. posted the faster year-over-year revenue change (44.7% vs -3.3%). ITRON, INC. produced more free cash flow last quarter ($79.0M vs $-69.0M). Over the past eight quarters, CLOVER HEALTH INVESTMENTS, CORP.'s revenue compounded faster (18.6% CAGR vs -1.8%).

Clover Health Investments, Corp. is an American health care company founded in 2014. The company provides Medicare Advantage (MA) insurance plans and operates as a direct contracting entity with the U.S. government. The company manages care for Medicare beneficiaries in 11 states and started trading publicly on January 8, 2021.

Itron, Inc. is an American technology company that offers products and services for energy and water resource management. It is headquartered in Liberty Lake, Washington, United States. The company's products measure and analyze electricity, gas and water consumption. Its products include electricity, gas, water and thermal energy measurement devices and control technology, communications systems, software, as well as managed and consulting services.

CLOV vs ITRI — Head-to-Head

Bigger by revenue
ITRI
ITRI
1.2× larger
ITRI
$587.0M
$487.7M
CLOV
Growing faster (revenue YoY)
CLOV
CLOV
+48.1% gap
CLOV
44.7%
-3.3%
ITRI
Higher net margin
ITRI
ITRI
19.2% more per $
ITRI
9.1%
-10.1%
CLOV
More free cash flow
ITRI
ITRI
$148.0M more FCF
ITRI
$79.0M
$-69.0M
CLOV
Faster 2-yr revenue CAGR
CLOV
CLOV
Annualised
CLOV
18.6%
-1.8%
ITRI

Income Statement — Q4 FY2025 vs Q1 FY2026

Metric
CLOV
CLOV
ITRI
ITRI
Revenue
$487.7M
$587.0M
Net Profit
$-49.3M
$53.6M
Gross Margin
40.3%
Operating Margin
-10.1%
11.5%
Net Margin
-10.1%
9.1%
Revenue YoY
44.7%
-3.3%
Net Profit YoY
-123.2%
-18.0%
EPS (diluted)
$1.18

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CLOV
CLOV
ITRI
ITRI
Q1 26
$587.0M
Q4 25
$487.7M
$571.7M
Q3 25
$496.6M
$581.6M
Q2 25
$477.6M
$606.8M
Q1 25
$462.3M
$607.2M
Q4 24
$337.0M
$612.9M
Q3 24
$331.0M
$615.5M
Q2 24
$356.3M
$609.1M
Net Profit
CLOV
CLOV
ITRI
ITRI
Q1 26
$53.6M
Q4 25
$-49.3M
$101.6M
Q3 25
$-24.4M
$65.6M
Q2 25
$-10.6M
$68.3M
Q1 25
$-1.3M
$65.5M
Q4 24
$-22.1M
$58.1M
Q3 24
$-9.2M
$78.0M
Q2 24
$7.4M
$51.3M
Gross Margin
CLOV
CLOV
ITRI
ITRI
Q1 26
40.3%
Q4 25
40.5%
Q3 25
37.7%
Q2 25
36.9%
Q1 25
35.8%
Q4 24
34.9%
Q3 24
24.5%
34.1%
Q2 24
30.3%
34.6%
Operating Margin
CLOV
CLOV
ITRI
ITRI
Q1 26
11.5%
Q4 25
-10.1%
13.8%
Q3 25
-4.9%
14.1%
Q2 25
-2.2%
12.6%
Q1 25
-0.3%
12.6%
Q4 24
-6.4%
10.2%
Q3 24
-2.7%
12.0%
Q2 24
2.0%
10.6%
Net Margin
CLOV
CLOV
ITRI
ITRI
Q1 26
9.1%
Q4 25
-10.1%
17.8%
Q3 25
-4.9%
11.3%
Q2 25
-2.2%
11.3%
Q1 25
-0.3%
10.8%
Q4 24
-6.6%
9.5%
Q3 24
-2.8%
12.7%
Q2 24
2.1%
8.4%
EPS (diluted)
CLOV
CLOV
ITRI
ITRI
Q1 26
$1.18
Q4 25
$2.20
Q3 25
$1.41
Q2 25
$1.47
Q1 25
$1.42
Q4 24
$1.26
Q3 24
$1.70
Q2 24
$1.10

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CLOV
CLOV
ITRI
ITRI
Cash + ST InvestmentsLiquidity on hand
$78.3M
$712.9M
Total DebtLower is stronger
Stockholders' EquityBook value
$308.7M
$1.6B
Total Assets
$541.0M
$4.0B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CLOV
CLOV
ITRI
ITRI
Q1 26
$712.9M
Q4 25
$78.3M
$1.0B
Q3 25
$1.3B
Q2 25
$1.2B
Q1 25
$1.1B
Q4 24
$194.5M
$1.1B
Q3 24
$288.0M
$982.5M
Q2 24
$254.8M
$920.6M
Total Debt
CLOV
CLOV
ITRI
ITRI
Q1 26
Q4 25
$1.3B
Q3 25
Q2 25
Q1 25
Q4 24
$1.3B
Q3 24
$1.3B
Q2 24
$1.3B
Stockholders' Equity
CLOV
CLOV
ITRI
ITRI
Q1 26
$1.6B
Q4 25
$308.7M
$1.7B
Q3 25
$340.9M
$1.7B
Q2 25
$344.2M
$1.6B
Q1 25
$336.1M
$1.5B
Q4 24
$341.1M
$1.4B
Q3 24
$342.2M
$1.3B
Q2 24
$324.9M
$1.2B
Total Assets
CLOV
CLOV
ITRI
ITRI
Q1 26
$4.0B
Q4 25
$541.0M
$3.7B
Q3 25
$559.7M
$3.7B
Q2 25
$575.0M
$3.6B
Q1 25
$583.7M
$3.5B
Q4 24
$580.7M
$3.4B
Q3 24
$653.0M
$3.4B
Q2 24
$674.2M
$3.3B
Debt / Equity
CLOV
CLOV
ITRI
ITRI
Q1 26
Q4 25
0.74×
Q3 25
Q2 25
Q1 25
Q4 24
0.91×
Q3 24
0.94×
Q2 24
1.02×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CLOV
CLOV
ITRI
ITRI
Operating Cash FlowLast quarter
$-66.9M
$85.5M
Free Cash FlowOCF − Capex
$-69.0M
$79.0M
FCF MarginFCF / Revenue
-14.1%
13.5%
Capex IntensityCapex / Revenue
0.4%
Cash ConversionOCF / Net Profit
1.60×
TTM Free Cash FlowTrailing 4 quarters
$-69.2M
$394.6M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CLOV
CLOV
ITRI
ITRI
Q1 26
$85.5M
Q4 25
$-66.9M
$119.3M
Q3 25
$12.1M
$117.8M
Q2 25
$5.4M
$96.7M
Q1 25
$-16.3M
$72.1M
Q4 24
$34.8M
$79.8M
Q3 24
$50.0M
$65.3M
Q2 24
$44.8M
$51.7M
Free Cash Flow
CLOV
CLOV
ITRI
ITRI
Q1 26
$79.0M
Q4 25
$-69.0M
$111.5M
Q3 25
$11.4M
$113.4M
Q2 25
$4.8M
$90.7M
Q1 25
$-16.5M
$67.5M
Q4 24
$33.3M
$70.2M
Q3 24
$49.6M
$58.7M
Q2 24
$44.4M
$44.6M
FCF Margin
CLOV
CLOV
ITRI
ITRI
Q1 26
13.5%
Q4 25
-14.1%
19.5%
Q3 25
2.3%
19.5%
Q2 25
1.0%
14.9%
Q1 25
-3.6%
11.1%
Q4 24
9.9%
11.4%
Q3 24
15.0%
9.5%
Q2 24
12.5%
7.3%
Capex Intensity
CLOV
CLOV
ITRI
ITRI
Q1 26
Q4 25
0.4%
1.4%
Q3 25
0.1%
0.8%
Q2 25
0.1%
1.0%
Q1 25
0.0%
0.8%
Q4 24
0.5%
1.6%
Q3 24
0.1%
1.1%
Q2 24
0.1%
1.2%
Cash Conversion
CLOV
CLOV
ITRI
ITRI
Q1 26
1.60×
Q4 25
1.17×
Q3 25
1.80×
Q2 25
1.41×
Q1 25
1.10×
Q4 24
1.37×
Q3 24
0.84×
Q2 24
6.04×
1.01×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

CLOV
CLOV

Segment breakdown not available.

ITRI
ITRI

Product revenues$477.8M81%
Service revenues$109.2M19%

Related Comparisons